SynthesisPLoS medicine2026
Urban and rural prevalence of tuberculosis in low- and middle-income countries: A systematic review and meta-analysis.
Synthesis in PLoS medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- AI-Driven Tuberculosis Hotspot Mapping to Optimize Active Case-Finding: Implementing the Epi-Control Platform in Uganda.Tropical medicine and infectious disease · 2026Article
- Association ofJournal of tropical medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUrban and rural settings differ in key determinants of tuberculosis (TB) burden, including transmission dynamics, social and structural determinants, and healthcare access. However, understanding of urban and rural TB burden is limited, hindering implementation of public health interventions to end TB. METHODS AND
findingsWe conducted a systematic review and meta-analysis of urban and rural differences in adult pulmonary TB prevalence in low- and middle-income countries. We searched PubMed, Embase, Global Health, the Cochrane Library, Africa Index Medicus, LILACS, and SciELO for community-representative prevalence surveys conducted between 1st January 1993 and 14th October 2025. Studies focussing solely on symptomatic or healthcare-seeking individuals and those conducted in congregate settings like prisons, universities, and health facilities were excluded. Risk of bias was assessed using a tool for prevalence surveys. Bayesian multilevel meta-regression was used to estimate pooled urban-to-rural prevalence ratios (PR) for bacteriologically-confirmed and smear-positive TB overall, and by World Health Organization (WHO) region. We also investigated time trends in the urban-to-rural prevalence ratio, and associations between urban-to-rural prevalence ratios and survey-level risk of bias (not low versus low), TB screening algorithm (whether used symptom screening for sputum eligibility), national TB incidence, percentage of population living in urban areas, and representativeness of prevalence surveys (national versus sub-national). To estimate the number of people with prevalent TB in urban and rural areas in study countries, and how these have changed between 2000 and 2024, we fitted a Bayesian multivariate model to WHO incidence and case detection ratio data and combined these estimates with assumptions about the duration of treated and untreated TB and the distribution of urban and rural populations. We included 47 surveys conducted between 2000 and 2024, encompassing 2,454,443 participants. The pooled urban-to-rural PR of bacteriologically-confirmed TB was 1.09 (95% credible interval [CrI]: 0.90, 1.30) and was 1.24 (95% CrI: 0.94, 1.61) for smear-positive TB. However, there were substantial differences between WHO regions: averaged across the 24 year study period the African Region had higher urban bacteriologically-confirmed prevalence (PR 1.18, 95% CrI: 0.91, 1.52), while the Western Pacific Region (PR 0.85, 95% CrI: 0.64, 1.07) and South-East Asia Region (PR 0.86, 95% CrI: 0.67, 1.08) had broadly similar urban and rural prevalence. Time trends indicated an increase in the overall bacteriologically-confirmed urban-to-rural prevalence ratio between 2000 and 2024, with a mean PR increase of 2.4% (95% CrI: -0.8%, 6.0%) per year. We estimated that, for 2024 in the 26 represented study countries (combined population: 2.24 billion [48.3%] urban; 2.40 billion [51.7%] rural), 49% (6.6 million, 95% CrI: 4.2, 12.0 million) of prevalent TB was in urban areas, and 51% (6.8 million, 95% CrI: 4.2, 12.0 million) in rural areas. Within countries, there were striking changes in the urban and rural distribution between 2000 and 2024, with the share of urban cases increasing in nearly all countries. The main limitations include lack of unified definitions for urban and rural areas, and absence of data for some global regions (e.g., Americas and Europe).
conclusionBetween 2000 and 2024, TB epidemics have become increasingly urbanised, both in proportional and absolute terms, although with considerable variation in timing across countries and regions. Public health approaches tailored to urban and rural TB epidemiology and demography will be required to end TB.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.